Calcium Phosphate [Milk source] + Vitamin D3 interactions

Checked as Calcium Phosphate + Cholecalciferol in this data source.

Full monograph for Calcium Phosphate [Milk source] + Vitamin D3 Check it against another medicine

Medicines

114 documented

Severity

Mechanism

Medicines documented to interact with Calcium Phosphate [Milk source] + Vitamin D3, worst severity first.
Medicine	Severity	Mechanism	Effect	Sources
Aluminium Hydroxide + Magnesium Hydroxidevia Cholecalciferol	Major	Absorption · Synergy	Chronic use of aluminum-containing preparations in patients with advanced renal impairment, particularly during treatment with vitamin D analogs, may result in…2 documented mechanisms	6 sources — open the full entry
Aluminium Hydroxide + Magnesium Hydroxide + Simethiconevia Cholecalciferol	Major	Absorption · Synergy	Chronic use of aluminum-containing preparations in patients with advanced renal impairment, particularly during treatment with vitamin D analogs, may result in…2 documented mechanisms	6 sources — open the full entry
Calcitriolvia Cholecalciferol	Major	Synergy	Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive…	5 sources — open the full entry
Calcium Citrate + Calcitriolvia Cholecalciferol	Major	Synergy	Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive…	5 sources — open the full entry
Doxercalciferolvia Cholecalciferol	Major	Synergy	Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive…	5 sources — open the full entry
Erdafitinibvia Calcium Phosphate, Cholecalciferol	Major	Others	Coadministration with agents that can alter serum phosphate levels may affect the initial dosage determination of erdafitinib. The mechanism appears to be…2 documented mechanisms	1 sources — open the full entry
Paricalcitolvia Cholecalciferol	Major	Synergy	Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive…	5 sources — open the full entry
Sucralfatevia Cholecalciferol	Major	Absorption	Chronic use of aluminum-containing preparations in patients with advanced renal impairment, particularly during treatment with vitamin D analogs, may result in…	2 sources — open the full entry
Alendronic acidvia Calcium Phosphate	Moderate	Absorption	INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to…	9 sources — open the full entry
Alendronic Acid + Vitamin D3via Calcium Phosphate	Moderate	Absorption	INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to…	9 sources — open the full entry
Aluminium Oxide + Magnesium Trisilicatevia Cholecalciferol	Moderate	Synergy	Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to…	4 sources — open the full entry
Amlodipine Besilatevia Calcium Phosphate	Moderate	Antagonism	Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been…	46 sources — open the full entry
Amlodipine Besilate + Atenololvia Calcium Phosphate	Moderate	Absorption · Antagonism	Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been…2 documented mechanisms	53 sources — open the full entry
Amlodipine Besilate + Atorvastatinvia Calcium Phosphate	Moderate	Antagonism	Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been…	46 sources — open the full entry
Amlodipine Besilate + Benazepril Hydrochloridevia Calcium Phosphate	Moderate	Antagonism	Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been…	46 sources — open the full entry
Amlodipine Besilate + Olmesartan Medoxomilvia Calcium Phosphate	Moderate	Antagonism	Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been…	46 sources — open the full entry
Amlodipine Besilate + Telmisartanvia Calcium Phosphate	Moderate	Antagonism	Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been…	46 sources — open the full entry
Amlodipine Besilate + Valsartanvia Calcium Phosphate	Moderate	Antagonism	Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been…	46 sources — open the full entry
Atenololvia Calcium Phosphate	Moderate	Absorption	INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism…	7 sources — open the full entry
Atenolol + Chlorthalidonevia Calcium Phosphate, Cholecalciferol	Moderate	Absorption · Synergy	INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism…3 documented mechanisms	22 sources — open the full entry
Azilsartan Medoxomil + Chlorthalidonevia Calcium Phosphate, Cholecalciferol	Moderate	Synergy	Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients…2 documented mechanisms	15 sources — open the full entry
Baloxavir Marboxilvia Calcium Phosphate	Moderate	Absorption	Coadministration with polyvalent cation-containing products may decrease the plasma concentrations and therapeutic efficacy of baloxavir. The proposed…	3 sources — open the full entry
Betaxolol Hydrochloridevia Calcium Phosphate	Moderate	Absorption	INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism…	7 sources — open the full entry
Bimatoprost + Timololvia Calcium Phosphate	Moderate	Absorption	INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism…	7 sources — open the full entry
Bisoprolol Fumaratevia Calcium Phosphate	Moderate	Absorption	INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism…	7 sources — open the full entry
Bisoprolol Fumarate + Amlodipine Besilatevia Calcium Phosphate	Moderate	Absorption · Antagonism	Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been…2 documented mechanisms	53 sources — open the full entry
Bisoprolol Fumarate + Hydrochlorothiazidevia Calcium Phosphate, Cholecalciferol	Moderate	Absorption · Synergy	Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients…3 documented mechanisms	22 sources — open the full entry
Brimonidine Tartrate + Timolol Maleatevia Calcium Phosphate	Moderate	Absorption	INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism…	7 sources — open the full entry
Brinzolamide + Timololvia Calcium Phosphate	Moderate	Absorption	INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism…	7 sources — open the full entry
Calcium acetate + Magnesium carbonatevia Cholecalciferol	Moderate	Synergy	Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to…	4 sources — open the full entry
Candesartan Cilexetil + Hydrochlorothiazidevia Calcium Phosphate, Cholecalciferol	Moderate	Synergy	Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients…2 documented mechanisms	15 sources — open the full entry
Carbamazepinevia Cholecalciferol	Moderate	Metabolism	Coadministration with CYP450 inducers such as rifampin, isoniazid, barbiturates, and certain anticonvulsants may decrease the pharmacologic effects of vitamin…	4 sources — open the full entry
Carvedilolvia Calcium Phosphate	Moderate	Absorption	INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism…	7 sources — open the full entry
Chlorthalidonevia Calcium Phosphate, Cholecalciferol	Moderate	Synergy	Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients…2 documented mechanisms	15 sources — open the full entry
Ciprofloxacinbase Ophthalmicvia Calcium Phosphate	Moderate	Absorption	INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics…	32 sources — open the full entry
Ciprofloxacin + Dexamethasonevia Calcium Phosphate	Moderate	Absorption	INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics…	32 sources — open the full entry
Ciprofloxacin + Hydrocortisone Acetatevia Calcium Phosphate	Moderate	Absorption	INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics…	32 sources — open the full entry
Clobetasol Propionate + Ofloxacin + Ornidazole + Terbinafinevia Calcium Phosphate	Moderate	Absorption	INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics…	32 sources — open the full entry
Deferipronevia Calcium Phosphate	Moderate	Absorption	INTERVAL: Deferiprone has the potential to bind polyvalent cations such as aluminum, iron and zinc, which may reduce its effectiveness. However, concurrent use…	1 sources — open the full entry
Delafloxacinvia Calcium Phosphate	Moderate	Absorption	INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics…	32 sources — open the full entry
Dexamethasone + Levofloxacinvia Calcium Phosphate	Moderate	Absorption	INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics…	32 sources — open the full entry
Digoxinvia Calcium Phosphate, Cholecalciferol	Moderate	Synergy	Excessive administration of calcium can aggravate digitalis toxicity and precipitate serious cardiac arrhythmias in digitalised patients. The mechanism…2 documented mechanisms	13 sources — open the full entry
Diltiazem Hydrochloridevia Calcium Phosphate	Moderate	Antagonism	Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been…	46 sources — open the full entry
Dorzolamide + Timololvia Calcium Phosphate	Moderate	Absorption	INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism…	7 sources — open the full entry
Doxycycline Hydrochloridevia Calcium Phosphate	Moderate	Absorption	INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed…	15 sources — open the full entry
Eltrombopag Olaminevia Calcium Phosphate	Moderate	Absorption	INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly…	4 sources — open the full entry
Fosphenytoin Sodiumvia Cholecalciferol	Moderate	Metabolism	Coadministration with CYP450 inducers such as rifampin, isoniazid, barbiturates, and certain anticonvulsants may decrease the pharmacologic effects of vitamin…	4 sources — open the full entry
Gatifloxacinvia Calcium Phosphate	Moderate	Absorption	INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics…	32 sources — open the full entry
Gatifloxacin + Dexamethasonevia Calcium Phosphate	Moderate	Absorption	INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics…	32 sources — open the full entry
Gemifloxacinvia Calcium Phosphate	Moderate	Absorption	INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics…	32 sources — open the full entry

Conditions

Conditions in which Calcium Phosphate [Milk source] + Vitamin D3 needs care, as documented in this source.

Arrhythmias, Cardiac
Major
Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides. Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias. Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.
3 sources
1. "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma (2001):
2. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories (2001):
3. "Product Information. Calderol (calcifediol)." Organon (2001):
Hypercalcemia
Major
Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.
4 sources
1. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories (2001):
2. "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical (2001):
3. "Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc (2002):
4. "Product Information. Drisdol (ergocalciferol)." sanofi-aventis (2016):
Kidney Diseases
Major
Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation. Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.
3 sources
1. "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma (2001):
2. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories (2001):
3. "Product Information. Calderol (calcifediol)." Organon (2001):
Water-Electrolyte Imbalance
Major
Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or renal systems or other soft tissue calcifications. A solubility product (Serum Calcium X Phosphate) should not exceed 70. Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.
4 sources
1. "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma (2001):
2. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories (2001):
3. "Product Information. Calderol (calcifediol)." Organon (2001):
4. "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical (2001):
Liver Diseases
Moderate
Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption. Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs. Metabolites of vitamin D analogs are primarily excreted in bile and feces. Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation. Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.
3 sources
1. "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma (2001):
2. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories (2001):
3. "Product Information. Calderol (calcifediol)." Organon (2001):

Therapeutic duplication

Drug classes that overlap with Calcium Phosphate [Milk source] + Vitamin D3, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.

vitamin d analogs
The recommended maximum number of medicines in the 'vitamin d analogs' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'vitamin d analogs' category.
Example product in the source data (US market): Os-cal extra d3

Medicines

Conditions

Arrhythmias, Cardiac

Hypercalcemia

Kidney Diseases

Water-Electrolyte Imbalance

Liver Diseases

Therapeutic duplication

vitamin d analogs